Apr 21, 2026 09:04AM
Apr 21, 2026 07:06AM
Apr 21, 2026 03:20AM
Apr 20, 2026 09:02AM
Apr 20, 2026 07:03AM
Apr 20, 2026 07:00AM
Apr 20, 2026 07:00AM Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Mar 31, 2026 02:12AM
Mar 30, 2026 04:02PM
Nov 10, 2025 04:15PM
Jan 10, 2025 07:11AM
Jan 10, 2025 07:00AM
Aug 8, 2024 07:00AM
Jul 16, 2024 07:00AM Passage Bio (PASG) Receives Positive FDA Feedback on Expansion of upliFT-D Trial of PBFT02
Jul 16, 2024 07:00AM
May 14, 2024 07:00AM
Aug 7, 2023 07:07AM
Aug 7, 2023 07:00AM
Feb 24, 2023 07:01AM
Feb 24, 2023 07:00AM
Feb 24, 2023 07:00AM Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
Feb 15, 2023 07:00AM
Feb 15, 2023 07:00AM
Dec 14, 2022 07:10AM
Dec 14, 2022 07:00AM
Dec 14, 2022 07:00AM
Aug 11, 2022 07:00AM
Aug 11, 2022 07:00AM Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations
Aug 4, 2022 07:00AM
Aug 4, 2022 07:00AM
Jun 8, 2022 07:30AM
Jun 8, 2022 07:30AM
Jun 8, 2022 07:30AM
May 18, 2022 07:02AM
May 18, 2022 07:00AM Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting
May 18, 2022 07:00AM
May 16, 2022 07:00AM
May 16, 2022 07:00AM
May 2, 2022 04:01PM
May 2, 2022 04:01PM
Mar 29, 2022 07:02AM
Mar 29, 2022 07:00AM Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease
Mar 29, 2022 07:00AM
Mar 10, 2022 07:00AM
Mar 10, 2022 07:00AM
Feb 11, 2022 11:00AM
Feb 11, 2022 11:00AM
Feb 11, 2022 11:00AM
Dec 17, 2021 07:01AM Passage Bio (PASG) Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
Dec 17, 2021 07:00AM

322,238 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All